– USA, CA – Avenzo Therapeutics, Inc., a clinical-stage biotechnology company developing next-generation oncology therapies for patients, announced the appointment of Pat Machado to its board of directors, bringing more than 20 years of biotech management and board experience for companies across the U.S., Canada, Europe, and Australia.
About Patrick Machado
Pat Machado co-founded Medivation, Inc., where he served as CBFO until 2014 and then as a member of Medivation’s board of directors until its acquisition by Pfizer in 2016. He serves as chairman of the board for Prota Therapeutics and Adverum Biotechnologies and as an independent director on the boards of ACELYRIN, Alumis, Arcus Biosciences, and Xenon Pharmaceuticals.
Pat Machado served on the board of directors for Turning Point Therapeutics, Principia Biopharma, Therachon, and Endocyte before their acquisitions.
“I am honored to become a member of the Avenzo board of directors,” said Pat Machado. “Avenzo’s executive team has a proven track record and deep expertise in oncology drug development. I look forward to working with my fellow board members and the executive team to advance the company’s growth and potentially bring new treatment options to cancer patients.”
Pat Machado earned a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.
About Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s lead drug candidate, AVZO-021, is a novel, highly potent, and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. AVZO-021 is being studied in a Phase 1 study in the U.S. for the treatment of advanced solid tumors in combination with HR+/HER2-negative metastatic breast cancer. Avenzo is headquartered in San Diego, California.
For more information: https://avenzotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.